Skip to main navigation
60 Degrees Pharma
Investor Relations
  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Corporate Governance
    • Governance Overview
    • Board of Directors
    • Executive Leadership Team
    • Committee Composition
  • Financial Information
    • SEC Filings
  • Stock Information
    • Stock Quote & Chart
  • Shareholder Services
    • Email Alerts
    • RSS Feeds
    • Contact IR

News Releases

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd , a majority-owned subsidiary of 60 Degrees Pharmaceuticals , has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use of tafenoquine in treating COVID-19; Company plans to resubmit a revised IND later in 2023,
September 18, 2023
PDF Version
Read More
60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Management investor presentation webcast available Monday 9/11, 7:00 AM ET Attendees may request 1 x 1 meetings with management at meetings@hcwco.com WASHINGTON , Sept. 06, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP ), a pharmaceutical company
September 6, 2023
PDF Version
Read More
60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity
Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp. Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market Presumed mode of action differentiated from standard of care treatment WASHINGTON , Aug.
August 30, 2023
PDF Version
Read More
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria
60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in naïve individuals Tafenoquine kills dormant liver stage of P. vivax  parasite and clears the blood stages of P.
August 22, 2023
PDF Version
Read More
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA ® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of disease progression, has been registered on ClinicalTrials.gov 60P’s majority-owned subsidiary, 60P
August 15, 2023
PDF Version
Read More
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects
Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035. Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals’ USFDA-approved drug for malaria prevention, ARAKODA ® . Most travelers from Canada and the United States
July 31, 2023
PDF Version
Read More
60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / July 21, 2023 /  RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Unicycive Therapeutics, Inc. (NASDAQ:UNCY) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 22, at 7 p.m. Eastern Time (ET).
July 21, 2023
PDF Version
Read More
60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering
WASHINGTON, July 14, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc., (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), specialists in developing and marketing medicines for infectious diseases, announced today the closing of its initial public offering of 1,415,095 units (each, a “Unit,”
July 14, 2023
PDF Version
Read More
WallachBeth Capital Announce Pricing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit
JERSEY CITY, N.J. , July 12, 2023 /PRNewswire/ -- WallachBeth Capital LLC , a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals, Inc. , (NASDAQ: SXTP; SXTPW) specialists in developing and marketing medicines for infectious
July 12, 2023
PDF Version
Read More
60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering
WASHINGTON , July 12, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc., (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), specialists in developing and marketing medicines for infectious diseases, announced today the pricing of its initial public offering of 1,415,095 units (each, a "Unit,"
July 12, 2023
PDF Version
Read More
60 Degrees Pharmaceuticals, Inc

1025 Connecticut Avenue NW
Suite 1000
Washington, DC 20036
P: 202-327-5422

Lorem ipsum dolor sit amet, consectetur adipiscing elit.
© 60 Degrees Pharmaceuticals, Inc. All Rights Reserved.
btn >> Footer icons
Search Investors